HomeAI · summaries
Storia in 15 fonti
mRNA melanoma vaccine-pembrolizumab combo shows survival gains in late-stage trial
A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk melanoma, according to topline data from the manufacturer.The randomized, double-blind INTerpath-001 trial evaluated intismeran autogene (intismeran; Merck, Moderna), an investigational mRNA-based individualized neoantigen
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
mRNA melanoma vaccine-pembrolizumab combo shows survival gains in late-stage trial
A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk…
- ·
en.mercopress.com
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…
